Renal Transplant Rejection and Tolerance
By:
Carrie A. Schinstock Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota

Search for other papers by Carrie A. Schinstock in
Current site
Google Scholar
PubMed
Close
and
Andrew J. Bentall Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota

Search for other papers by Andrew J. Bentall in
Current site
Google Scholar
PubMed
Close
  • Collapse
  • Expand
  • 1

    Loupy A, Haas M, Roufosse C, Naesens M, Adam B, Afrouzian M, et al.: The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant 20: 23182331, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2

    Nankivell BJ, Shingde M, Keung KL, Fung CL, Borrows RJ, O’Connell PJ, et al.: The causes, significance and consequences of inflammatory fibrosis in kidney transplantation: The Banff i-IFTA lesion. Am J Transplant 18: 364376, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3

    Mannon RB, Matas AJ, Grande J, Leduc R, Connett J, Kasiske B, et al.; DeKAF Investigators: Inflammation in areas of tubular atrophy in kidney allograft biopsies: A potent predictor of allograft failure. Am J Transplant 10: 20662073, 2010 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4

    Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D, et al.: The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant 18: 293307, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5

    Nakagawa K, Tsuchimoto A, Ueki K, Matsukuma Y, Okabe Y, Masutani K, et al.; Japan Academic Consortium of Kidney Transplantation Investigators: Significance of revised criteria for chronic active T cell-mediated rejection in the 2017 Banff classification: Surveillance by 1-year protocol biopsies for kidney transplantation. Am J Transplant 21: 174185, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6

    Matas AJ, Helgeson ES, Gaston R, Cosio F, Mannon R, Kasiske BL, et al.: Inflammation in areas of fibrosis: The DeKAF prospective cohort. Am J Transplant 20: 25092521, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7

    Schinstock CA, Sapir-Pichhadze R, Naesens M, Batal I, Bagnasco S, Bow L, et al.: Banff survey on antibody-mediated rejection clinical practices in kidney transplantation: Diagnostic misinterpretation has potential therapeutic implications. Am J Transplant 19: 123131, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8

    Callemeyn J, Ameye H, Lerut E, Senev A, Coemans M, Van Loon E, et al.: Revisiting the changes in the Banff classification for antibody-mediated rejection after kidney transplantation. Am J Transplant 21: 24132423, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9

    Mengel M, Loupy A, Haas M, Roufosse C, Naesens M, Akalin E, et al.: Banff 2019 Meeting Report: Molecular diagnostics in solid organ transplantation-Consensus for the Banff Human Organ Transplant (B-HOT) gene panel and open source multicenter validation. Am J Transplant 20: 23052317, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10

    Clayton PA, McDonald SP, Russ GR, Chadban SJ: Long-term outcomes after acute rejection in kidney transplant recipients: An ANZDATA analysis. J Am Soc Nephrol 30: 16971707, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11

    Van Loon E, Senev A, Lerut E, Coemans M, Callemeyn J, Van Keer JM, et al.: Assessing the complex causes of kidney allograft loss. Transplantation 104: 25572566, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12

    Hoffman W, Mehta R, Jorgensen DR, Sood P, Randhawa P, Wu CM, et al.: The impact of early clinical and subclinical T cell-mediated rejection after kidney transplantation. Transplantation 103: 14571467, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13

    Gupta A, Broin PO, Bao Y, Pullman J, Kamal L, Ajaimy M, et al.: Clinical and molecular significance of microvascular inflammation in transplant kidney biopsies. Kidney Int 89: 217225, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14

    Grafft CA, Cornell LD, Gloor JM, Cosio FG, Gandhi MJ, Dean PG, et al.: Antibody-mediated rejection following transplantation from an HLA-identical sibling. Nephrol Dial Transplant 25: 307310, 2010 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15

    Parajuli S, Redfield RR, Garg N, Aziz F, Mohamed M, Astor BC, et al.: Clinical significance of microvascular inflammation in the absence of anti-HLA DSA in kidney transplantation. Transplantation 103: 14681476, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16

    Sis B, Jhangri GS, Riopel J, Chang J, de Freitas DG, Hidalgo L, et al.: A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant 12: 11681179, 2012 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17

    Senev A, Coemans M, Lerut E, Van Sandt V, Daniëls L, Kuypers D, et al.: Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: Clinical presentation and implications for outcome. Am J Transplant 19: 763780, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18

    Senev A, Lerut E, Van Sandt V, Coemans M, Callemeyn J, Sprangers B, et al.: Specificity, strength, and evolution of pretransplant donor-specific HLA antibodies determine outcome after kidney transplantation. Am J Transplant 19: 31003113, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19

    Lefaucheur C, Louis K, Philippe A, Loupy A, Coates PT: The emerging field of non-human leukocyte antigen antibodies in transplant medicine and beyond. Kidney Int 100: 787798, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20

    Lefaucheur C, Viglietti D, Bouatou Y, Philippe A, Pievani D, Aubert O, et al.: Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. Kidney Int 96: 189201, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21

    Davis S, Gralla J, Klem P, Stites E, Wiseman A, Cooper JE: Tacrolimus intrapatient variability, time in therapeutic range, and risk of de novo donor-specific antibodies. Transplantation 104: 881887, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22

    Gonzales HM, McGillicuddy JW, Rohan V, Chandler JL, Nadig SN, Dubay DA, et al.: A comprehensive review of the impact of tacrolimus intrapatient variability on clinical outcomes in kidney transplantation. Am J Transplant 20: 19691983, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23

    Schinstock CA, Dadhania DM, Everly MJ, Smith B, Gandhi M, Farkash E, et al.: Factors at de novo donor-specific antibody initial detection associated with allograft loss: A multicenter study. Transpl Int 32: 502515, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24

    Schinstock CA, Cosio F, Cheungpasitporn W, Dadhania DM, Everly MJ, Samaniego-Picota MD, et al.: The value of protocol biopsies to identify patients with de novo donor-specific antibody at high risk for allograft loss. Am J Transplant 17: 15741584, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25

    Nevins TE, Nickerson PW, Dew MA: Understanding medication nonadherence after kidney transplant. J Am Soc Nephrol 28: 22902301, 2017 PubMed

  • 26

    Lim WH, Chapman JR, Coates PT, Lewis JR, Russ GR, Watson N, et al.: HLA-DQ mismatches and rejection in kidney transplant recipients. Clin J Am Soc Nephrol 11: 875883, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27

    DeVos JM, Gaber AO, Knight RJ, Land GA, Suki WN, Gaber LW, et al.: Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. Kidney Int 82: 598604, 2012 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28

    Duquesnoy RJ, Askar M: HLAMatchmaker: A molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ, and HLA-DP. Hum Immunol 68: 1225, 2007 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29

    Wiebe C, Kosmoliaptsis V, Pochinco D, Gibson IW, Ho J, Birk PE, et al.: HLA-DR/DQ molecular mismatch: A prognostic biomarker for primary alloimmunity. Am J Transplant 19: 17081719, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30

    Senev A, Coemans M, Lerut E, Van Sandt V, Kerkhofs J, Daniëls L, et al.: Eplet mismatch load and de novo occurrence of donor-specific anti-HLA antibodies, rejection, and graft failure after kidney transplantation: An observational cohort study. J Am Soc Nephrol 31: 21932204, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31

    Kramer C, Heidt S, Claas FHJ: Towards the identification of the relative immunogenicity of individual HLA antibody epitopes. Hum Immunol 80: 218220, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32

    Tambur AR, Kosmoliaptsis V, Claas FHJ, Mannon RB, Nickerson P, Naesens M: Significance of HLA-DQ in kidney transplantation: Time to reevaluate human leukocyte antigen-matching priorities to improve transplant outcomes? An expert review and recommendations. Kidney Int 100: 10121022, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33

    Schinstock CA, Mannon RB, Budde K, Chong AS, Haas M, Knechtle S, et al.: Recommended treatment for antibody-mediated rejection after kidney transplantation: The 2019 Expert Consensus from the Transplantation Society Working Group. Transplantation 104: 911922, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34

    Bailly E, Ville S, Blancho G, Morelon E, Bamoulid J, Caillard S, et al.: An extension of the RITUX-ERAH study, multicenter randomized clinical trial comparing rituximab to placebo in acute antibody-mediated rejection after renal transplantation. Transpl Int 33: 786795, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35

    Sautenet B, Blancho G, Büchler M, Morelon E, Toupance O, Barrou B, et al.: One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial. Transplantation 100: 391399, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36

    Marks WH, Mamode N, Montgomery RA, Stegall MD, Ratner LE, Cornell LD, et al.; C10-001 Study Group: Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial. Am J Transplant 19: 28762888, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37

    Glotz D, Russ G, Rostaing L, Legendre C, Tufveson G, Chadban S, et al.; C10-002 Study Group: Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies. Am J Transplant 19: 28652875, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38

    Schinstock CA, Bentall AJ, Smith BH, Cornell LD, Everly M, Gandhi MJ, et al.: Long-term outcomes of eculizumab-treated positive crossmatch recipients: Allograft survival, histologic findings, and natural history of the donor-specific antibodies. Am J Transplant 19: 16711683, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39

    Tan EK, Bentall A, Dean PG, Shaheen MF, Stegall MD, Schinstock CA: Use of eculizumab for active antibody-mediated rejection that occurs early post-kidney transplantation: A consecutive series of 15 cases. Transplantation 103: 23972404, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40

    Montgomery RA, Orandi BJ, Racusen L, Jackson AM, Garonzik-Wang JM, Shah T, et al.: Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: Results of a randomized double-blind placebo-controlled pilot study. Am J Transplant 16: 34683478, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41

    Viglietti D, Gosset C, Loupy A, Deville L, Verine J, Zeevi A, et al.: C1 inhibitor in acute antibody-mediated rejection nonresponsive to conventional therapy in kidney transplant recipients: A pilot study. Am J Transplant 16: 15961603, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42

    Doberer K, Kläger J, Gualdoni GA, Mayer KA, Eskandary F, Farkash EA, et al.: CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection. Transplantation 105: 451457, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43

    Jain D, Rajab A, Young JS, Yin D, Nadasdy T, Chong AS, et al.: Reversing donor-specific antibody responses and antibody-mediated rejection with bortezomib and belatacept in mice and kidney transplant recipients. Am J Transplant 20: 26752685, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44

    Jordan SC, Legendre C, Desai NM, Lorant T, Bengtsson M, Lonze BE, et al.: Imlifidase desensitization in crossmatch-positive, highly sensitized kidney transplant recipients: Results of an international phase 2 trial (Highdes). Transplantation 105: 18081817, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45

    Jordan SC, Choi J, Kim I, Wu G, Toyoda M, Shin B, et al.: Interleukin-6, A cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: Therapeutic implications of IL-6 receptor blockade. Transplantation 101: 3244, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46

    Shin BH, Everly MJ, Zhang H, Choi J, Vo A, Zhang X, et al.: Impact of tocilizumab (anti-IL-6R) treatment on immunoglobulins and anti-HLA antibodies in kidney transplant patients with chronic antibody-mediated rejection. Transplantation 104: 856863, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47

    Pottebaum AA, Venkatachalam K, Liu C, Brennan DC, Murad H, Malone AF, et al.: Efficacy and safety of tocilizumab in the treatment of acute active antibody-mediated rejection in kidney transplant recipients. Transplant Direct 6: e543, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48

    Choi J, Aubert O, Vo A, Loupy A, Haas M, Puliyanda D, et al.: Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients. Am J Transplant 17: 23812389, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49

    Massat M, Congy-Jolivet N, Hebral AL, Esposito L, Marion O, Delas A, et al.; Toulouse Acquired Immune Deficiency, Infection (TAIDI) Study Group: Do anti-IL-6R blockers have a beneficial effect in the treatment of antibody-mediated rejection resistant to standard therapy after kidney transplantation? Am J Transplant 21: 16411649, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50

    Eskandary F, Dürr M, Budde K, Doberer K, Reindl-Schwaighofer R, Waiser J, et al.: Clazakizumab in late antibody-mediated rejection: Study protocol of a randomized controlled pilot trial. Trials 20: 37, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51

    Doberer K, Duerr M, Halloran PF, Eskandary F, Budde K, Regele H, et al.: A randomized clinical trial of anti-IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection. J Am Soc Nephrol 32: 708722, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52

    CSL Behring: Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients (IMAGINE), 2021. Available at: https://clinicaltrials.gov/ct2/show/NCT03744910. Accessed August 15, 2021

    • PubMed
    • Export Citation
  • 53

    Billingham RE, Brent L, Medawar PB: Actively acquired tolerance of foreign cells. Nature 172: 603606, 1953 PubMed

  • 54

    Rickert CG, Markmann JF: Current state of organ transplant tolerance. Curr Opin Organ Transplant 24: 441450, 2019 PubMed

  • 55

    Newell KA, Adams AB, Turka LA: Biomarkers of operational tolerance following kidney transplantation: The immune tolerance network studies of spontaneously tolerant kidney transplant recipients. Hum Immunol 79: 380387, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56

    Sagoo P, Perucha E, Sawitzki B, Tomiuk S, Stephens DA, Miqueu P, et al.: Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 120: 18481861, 2010 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57

    Busque S, Scandling JD, Lowsky R, Shizuru J, Jensen K, Waters J, et al.: Mixed chimerism and acceptance of kidney transplants after immunosuppressive drug withdrawal. Sci Transl Med 12: eaax8863, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58

    Scandling JD, Busque S, Shizuru JA, Lowsky R, Hoppe R, Dejbakhsh-Jones S, et al.: Chimerism, graft survival, and withdrawal of immunosuppressive drugs in HLA matched and mismatched patients after living donor kidney and hematopoietic cell transplantation. Am J Transplant 15: 695704, 2015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59

    Leventhal J, Galvin J, Mathew J, Gallon L, Stare D, Sweeney A, Miller J, Abecassis M, Ildstad S. Eight year follow-up of a phase 2 clinical trial to induce tolerance in living donor renal transplant recipients. Am J Transplant 17(Suppl 3): 276, 2017

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60

    Issa F, Strober S, Leventhal JR, Kawai T, Kaufman DB, Levitsky J, et al.: The Fourth International Workshop on Clinical Transplant Tolerance. Am J Transplant 21: 2131, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61

    Sellberg F, Berglund D, Binder C, Hope J, Fontenot J, Griesemer A, et al.: Pharmacokinetic and pharmacodynamic study of a clinically effective anti-CD2 monoclonal antibody. Scand J Immunol 91: e12839, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 772 123 4
Full Text Views 745 176 11
PDF Downloads 1066 261 17